COPD Flashcards

1
Q

what is COPD?

A

Chronic: progressive and long lasting
Obstructive: narrowing of airways that causes airflow limitation
Pulmonary: small airways and/or alveoli destruction
Disease: multicomponent illness with extra-pulmonary effects

Characterised by airflow limitation that is NOT fully reversible.
Progressive and associated with an abnormal inflammatory response of the lungs to noxious particles and gases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the airflow limitations of COPD caused by?

A

Airflow limitation is caused by a mixture of small airway disease and parenchymal destruction: chronic bronchitis and emphysema.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the risk factors of COPD?

A
Smoking (~80% of COPD) 
Enviromental pollution 
Genetic factor
Occupational exposure 
Frequent infections of the airways

Age > 35
Socio-economical deprivation
Poor diet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

symptoms of COPD?

A

Progressive and exertional breathlessness (dyspnea)
Chronic cough
Sputum production
Wheezing and chest tightness
Frequent winter bronchitis
Upper respiratory infection (purulent sputum)
Pulmonary hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are the symptoms in severe COPD?

A
In severe COPD:
 Weight loss, anorexia
 Asymptomatic rib fractures
 Ankle swelling
 Depression, anxiety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

A diagnosis of COPD should be considered in:

A

A diagnosis of COPD should be considered in:
patients over the age of 35
who have a risk factor (generally smoking)
who present with exertional breathlessness, chronic cough, regular sputum production, frequent winter ‘bronchitis’ or wheeze. [2004]
The presence of airflow obstruction should be confirmed by performing post-bronchodilator spirometry.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

COPD pathophysiology : emphysema?

what is emphysema and its causes?

A

Emphysema: persistent inflammation destroys alveoli at the end of small airways.

Permanent enlargement of the air spaces distal to the terminal bronchiole accompanied by destruction of their walls.
Destruction of the parenchyma decreases the area for gas exchange and lung elasticity
Hypertrophy of capillaries reduces ability to absorb oxygen and may increase blood pressure.

The alveoli have a good blood supply and the oxygen from the air that a person breathes in is transferred into their bloodstream from the alveoli. If the alveoli are damaged (as in emphysema), this oxygen transfer becomes affected. Thus, it is harder to absorb oxygen
Lungs less able to contract and expel air on breathing out
Since the lungs are damaged, the amount of oxygen that goes to the blood is reduced. This produces high blood pressure in the blood vessels from the heart to the lungs, and makes it even more difficult for the heart to pump much-needed blood to the rest of the body. This lung disease can also cause the body to produce more red blood cells, which can make the blood thicker and harder to pump. The COPD and hypertension working together forces the person to breathe faster in order to take in more oxygen
Pulmonary hypertension in COPD patients is caused by the loss of alveolar structure, remodeling of the pulmonary vessels by chronic hypoxia and inflammation, decreases in the levels of endothelial vasodilators such as nitric oxide, and vasospasm caused by factors such as endothelin-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

COPD pathophysiology : chronic bronchitis and bronchilitis?

what is chronic bronchitis and its causes?

A

Chronic bronchitis and Bronchiolitis: Inflammation of central airways (trachea/bronchi) and smaller airways (bronchioles)

Hypertrophy and hyperplasia occur to the mucus-secreting glands and smooth muscle in smaller airways
Small airways become obstructed by intraluminal mucus, mucosal oedema and airways wall fibrosis.
The obstruction and the mucus increase resistance to airflow and cause chronic viral and bacterial colonisation in the retained mucus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the pathogenesis of COPD

A

1) Inflammatory cells and mediators
Chronic Inflammation
(neutrophils produces proteinase and leukotrines
macrophages produces cytokines and chemokines

2) Oxidative stress
Reactive oxygen and nitrogen species
(causes oxidation of lipids, proteins and DNA
increase in transcription of pro-imflammatory proteins
increase in protease activations
decrease in antiprotease
aptosis)

Imbalance between oxidant and antioxidant damage to intracellular matrix oxidation of biological molecules cell destruction
Acetylation of histone due to impairment of histone deacetylase
Oxidative stress casues Alveolar epithelial injury and remodeling of extracellular matrix

3) Protease-antiprotease imbalance
a1-antitrypsin deficit

A1AT helps to balance the protease enzymes in the lungs and stop lung damage.
Its main function is to protect the lungs from damage caused by other types of proteins called enzymes.
Alpha-1 antitrypsin (A1AT) deficiency is an inherited genetic condition (a condition that can be passed on from your parents through your genes). It can lead to lung and, in some people, liver damage
In COPD there is an increase production/activity of proteineses or there is reduction of activity/production of antiproteinases alfa1-antitrypsin.
deficit increase risk of COPD maybe COPD inactivate alpha1 anti-proteinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the clinical differences between asthma and COPD

A

smokers/ ex - smokers = nearly ALL COPD
symptoms under 35 - Rare in COPD
chronic productive cough - common in COPD
Breathlessness - persistent and progressive in COPD
night time waking up with breathlessness - common in asthma
day to day variability in symptoms - asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The severity of COPD - FEV1 %

A

> 80 = mild
50-79 = moderate
30-49 = severe
less than 30 = very severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the aims of managing stable COPD?

A

AIMS
Prevent and control symptoms
Reduce the frequency and severity of exacerbations
Improve general health status and exercise tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are non- pharmacological management for COPD?

A
  • offer treatment and support to stop smoking
  • offer influenza and pneumococcal vaccination
  • offer pulmonary rehab
  • self management plans
  • optimise treatment for comorbidities

Rationale:
Reduce the frequency and severity of exacerbations
Improve general health

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

when should inhaled therapy be used in COPD?

A
  • if non-pharmacological treatment was offered
  • inhaled therapy is needed to help breathlessness and exercise limitations
    -they have been trained to use the inhaler with good technique
    : offer SABA or SAMA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the mechanism of b2 Adrenoceptor Agonists

A

Mechanism of action
Activate b2AR in airway smooth muscle
Cause airway smooth muscle relaxation by cAMP-dependent (and independent?) mechanism

β-agonist binds to β2-AR, activating adenyl cyclase through Gαs, leading to an increase in cAMP levels. The surge in cAMP in turn activates PKA which phosphorylates myosin light chain kinase to inhibit contraction. PKA also activates K+channels, inducing membrane hyperpolarization which counteracts electrical excitation leading to contraction.

Moreover, cAMP inhibits Ca2+ release from intracellular store
All of which aid relaxation of the airway smooth muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the role of muscarinic receptor in the lungs

M1:

A

M1 receptors may mediate bronchodilation, by the release of a relaxing agent from respiratory epithelia or pulmonary nerves

17
Q

what is the role of muscarinic receptor in the lungs

M2:

A

M2 autoreceptors, on post-ganglionic cholinergic nerves: provide negative feedback to reduce acetylcholine release

18
Q

what is the role of muscarinic receptor in the lungs

M3:

A

M3 on airway smooth muscle cells and glands: mediate bronchoconstriction and mucus secretion

19
Q

what is the mechanism of action of Inhaled Anticholinergics Drugs

A

Mechanism of action

Block muscarinic acetylcholine receptors (M3) to cause bronchodilation and reduce mucus secretion

20
Q

what is an example of Short-acting antimuscarinic drugs

A
Ipratropium Bromide (SAMA) 
Onset after 20 minutes peak effect within 30-60 minutes, and duration of action3 to 6 hours
21
Q

what is an example of Short-acting antimuscarinic drugs

A

Long-acting antimuscarinic drugs
Tiotropium Bromide (LAMA)
Onset of action 30 minutes, peak effect within 3 to 4 hours, and 24-hour duration of action

22
Q

what are the side effects of Inhaled anticholinergics drugs

A

Common: dry mouth; arrhythmias;cough;dizziness;headache;nausea

Uncommon: Constipation; dysphonia; glaucoma; palpitations; skin reactions; stomatitis; urinary disorders; vision blurred

23
Q

what are the side effects of tiotropium

A

Caution

Tiotropium: arrhythmia,heart failure,myocardial infarction

24
Q

when is the Use of inhaled combination therapies used

A

if
the person is limited by symptoms or has excerbation despite treatment

no asthmatic features or features suggesting steroid responsiveness : Offer LABA or LAMA

asthmatic features or features suggesting steroid responsiveness : Consider LABA and ICS

25
Q

The last step is

A

LABA + LAMA and ICS

If no improvement revert to LABA And LAMA

26
Q

what are further treatment option

A

Oral corticosteroid maintenance therapy NOT normally recommended

Mucolytic drug therapy
Considered in patients with a chronic cough productive of sputum

Long-acting phosphodiesterase-4 inhibitor
Theophylline: after a trial of inhaled combination therapy in patients unable to use inhaled therapy
Roflumilast

Maintenance use of oral corticosteroid therapy in COPD is not normally recommended.

Mucolytic drug therapy should be considered in patients with a chronic cough productive of sputum.

Theophylline should only be used after a trial of short-acting bronchodilators and long-acting bronchodilators, or in patients who are unable to use inhaled therapy, as there is a need to monitor plasma levels and interactions.

Roflumilast, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis

27
Q
Oral inhibitor of phosphodiesterase-4 
Example 
Mechanism 
Use
Side effect
A

Roflumilast (Daxas)

Mechanism of action:
Selective inhibition of the PDE4 isoenzyme in lung cells
Unclear mechanism of action

Use:
Oral add-on to bronchodilator therapy, for severe COPD associated with chronic bronchitis and prevention of exacerbations

Side Effects:
Common: diarrhoea, weight loss and nausea
Increase in psychiatric adverse reactions

28
Q

what is exacerbation

A

Exacerbation= A sustained acute-onset worsening of the person’s symptoms from their usual stable state, which
goes beyond their normal day-to-day variations
Worsening breathlessness, cough, increased sputum production and change in sputum colour

29
Q

Corticosteroids and COPD

A

Little clinical benefit in COPD!
Reduce but DO NOT suppress lung inflammation and secretion of inflammatory proteins!

Reduce incidence of exacerbations BUT give higher incidence of pneumonia (immune suppression)

DO NOT reduce mortality or progression of disease but reduce requirement for systemic glucocorticoids and hospitalisation rate.

Licenced in UK only in combiantion with LABA!

30
Q

What is the summary of the treatment plan for COPD

A
  • non-pharmacological
  • SABA or SAMA
  • LABA and LAMA or LABA and ICS (combined)
  • LABA + LAMA + ICS